GEAP202416425A - Imidazole-containing inhibitors of alk2 kinase - Google Patents
Imidazole-containing inhibitors of alk2 kinaseInfo
- Publication number
- GEAP202416425A GEAP202416425A GEAP202416425A GEAP2024016425A GEAP202416425A GE AP202416425 A GEAP202416425 A GE AP202416425A GE AP202416425 A GEAP202416425 A GE AP202416425A GE AP2024016425 A GEAP2024016425 A GE AP2024016425A GE AP202416425 A GEAP202416425 A GE AP202416425A
- Authority
- GE
- Georgia
- Prior art keywords
- iii
- imidazole
- pharmaceutically acceptable
- compounds
- alk2 kinase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163192822P | 2021-05-25 | 2021-05-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GEAP202416425A true GEAP202416425A (en) | 2024-02-12 |
Family
ID=84230377
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GEAP202416425A GEAP202416425A (en) | 2021-05-25 | 2022-05-24 | Imidazole-containing inhibitors of alk2 kinase |
Country Status (23)
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022407047A1 (en) * | 2021-12-08 | 2024-07-25 | Kineta, Inc. | Bicyclic heteroarenes and methods of their use |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5405848A (en) * | 1993-12-22 | 1995-04-11 | Ortho Pharmaceutical Corporation | Substituted thiazolylaminotetrahydropyridopyrimidines derivatives useful as platelet aggregation inhibitors |
| BR0111754A (pt) * | 2000-06-28 | 2003-04-29 | Astrazeneca Ab | Uso de um composto, método para inibir aurora 2 quinase em um animal de sangue quente, composto, e, composição farmacêutica |
| US20070244114A1 (en) * | 2004-07-06 | 2007-10-18 | Myriad Genetics, Incorporated | Compounds and therapeutical use thereof |
| JP2012504157A (ja) * | 2008-09-30 | 2012-02-16 | アストラゼネカ アクチボラグ | 複素環式jakキナーゼ阻害剤 |
| JP6121658B2 (ja) * | 2011-06-29 | 2017-04-26 | 大塚製薬株式会社 | 治療用化合物、及び関連する使用の方法 |
| CN108239071B (zh) * | 2016-12-27 | 2020-12-04 | 沈阳药科大学 | 酰胺及硫代酰胺类衍生物及其制备方法和应用 |
| AR112027A1 (es) * | 2017-06-15 | 2019-09-11 | Biocryst Pharm Inc | Inhibidores de alk 2 quinasa que contienen imidazol |
| JP7659269B2 (ja) * | 2018-12-21 | 2025-04-09 | ユニバーシティ・オブ・ノートル・ダム・デュ・ラック | 抗酸菌症治療のためのbdオキシダーゼ阻害剤の発見 |
-
2022
- 2022-05-24 GE GEAP202416425A patent/GEAP202416425A/en unknown
- 2022-05-24 CA CA3219966A patent/CA3219966A1/en active Pending
- 2022-05-24 BR BR112023024537A patent/BR112023024537A2/pt unknown
- 2022-05-24 CN CN202280037483.5A patent/CN117529315A/zh active Pending
- 2022-05-24 UY UY0001039788A patent/UY39788A/es unknown
- 2022-05-24 PE PE2023003085A patent/PE20250022A1/es unknown
- 2022-05-24 JP JP2023571902A patent/JP2024520359A/ja active Pending
- 2022-05-24 EP EP22811963.2A patent/EP4346806A4/en active Pending
- 2022-05-24 AR ARP220101377A patent/AR125963A1/es unknown
- 2022-05-24 MX MX2023013742A patent/MX2023013742A/es unknown
- 2022-05-24 KR KR1020237042819A patent/KR20240013145A/ko active Pending
- 2022-05-24 AU AU2022283258A patent/AU2022283258A1/en active Pending
- 2022-05-24 IL IL308513A patent/IL308513A/en unknown
- 2022-05-24 PY PY202202240952A patent/PY2240952A/es unknown
- 2022-05-24 WO PCT/US2022/030690 patent/WO2022251188A2/en not_active Ceased
- 2022-05-24 CR CR20230597A patent/CR20230597A/es unknown
- 2022-05-24 US US18/562,115 patent/US20240270750A1/en active Pending
- 2022-05-25 TW TW111119373A patent/TW202313625A/zh unknown
-
2023
- 2023-11-16 DO DO2023000254A patent/DOP2023000254A/es unknown
- 2023-11-23 JO JOJO/P/2023/0303A patent/JOP20230303A1/ar unknown
- 2023-11-24 CL CL2023003503A patent/CL2023003503A1/es unknown
- 2023-12-20 CO CONC2023/0017975A patent/CO2023017975A2/es unknown
- 2023-12-22 EC ECSENADI202396182A patent/ECSP23096182A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112023024537A2 (pt) | 2024-02-06 |
| UY39788A (es) | 2023-01-31 |
| JP2024520359A (ja) | 2024-05-24 |
| IL308513A (en) | 2024-01-01 |
| PY2240952A (es) | 2022-12-26 |
| EP4346806A2 (en) | 2024-04-10 |
| DOP2023000254A (es) | 2023-12-29 |
| US20240270750A1 (en) | 2024-08-15 |
| CA3219966A1 (en) | 2022-12-01 |
| AR125963A1 (es) | 2023-08-30 |
| ECSP23096182A (es) | 2024-01-31 |
| JOP20230303A1 (ar) | 2023-11-23 |
| MX2023013742A (es) | 2023-11-28 |
| WO2022251188A3 (en) | 2023-01-05 |
| AU2022283258A1 (en) | 2024-01-04 |
| KR20240013145A (ko) | 2024-01-30 |
| PE20250022A1 (es) | 2025-01-07 |
| CR20230597A (es) | 2024-02-20 |
| CL2023003503A1 (es) | 2024-05-03 |
| WO2022251188A8 (en) | 2024-01-04 |
| WO2022251188A2 (en) | 2022-12-01 |
| CO2023017975A2 (es) | 2024-01-15 |
| EP4346806A4 (en) | 2025-07-23 |
| CN117529315A (zh) | 2024-02-06 |
| TW202313625A (zh) | 2023-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023004309A (es) | Inhibidores de quinasa alk2 que contienen imidazol. | |
| SA522432955B1 (ar) | Kras g12c مثبطات | |
| JOP20250246A1 (ar) | مثبطات kras | |
| PH12021552482A1 (en) | Compounds targeting prmt5 | |
| PH12018502227A1 (en) | Macrocyclic mcl1 inhibitors for treating cancer | |
| CR20200503A (es) | Inhibidores de cinasa dependientes de ciclina | |
| EA202190686A1 (ru) | 5-7-членные гетероциклические амиды в качестве ингибиторов jak | |
| EA202190681A1 (ru) | Амиды диметиламиноазетидина в качестве jak ингибиторов | |
| PH12021550825A1 (en) | Quinoline derivatives as alpha4beta7 integrin inhibitors | |
| PH12020552244A1 (en) | Heterocyclic compounds as trk inhibitors | |
| MX2022008487A (es) | Degradadores de smarca2-vhl. | |
| JOP20220228A1 (ar) | مركبات بيرولو بيريميدين أمينات كمثبطات للمُتَمِّمِة | |
| EP4316504A3 (en) | Compounds | |
| BR112022001922A2 (pt) | Compostos de heteroarila de anel fundido como inibidores de ripk1 | |
| MX2023004008A (es) | Derivados de tetrazol como inhibidores de trpa1. | |
| SA523440367B1 (ar) | مشتقات تترازول كمثبطات لمستقبل عابر أنكيرين قوي 1 | |
| EA202192760A1 (ru) | Трициклические соединения | |
| MX2024011755A (es) | Derivados sulfonamidicos como inhibidores de la cinasa dependiente de ciclina 2 (cdk2) | |
| JOP20230303A1 (ar) | مثبطات كيناز alk2 تحتوي على إيميدازول | |
| JOP20240119A1 (ar) | مشتقات نافثيريدينون لمعالجة مرض أو اضطراب | |
| EA202192382A1 (ru) | Соединения, нацеленные на prmt5 | |
| EA202190689A1 (ru) | Производные хинолина в качестве ингибиторов интегрина альфа4бета7 | |
| MX2025006793A (es) | Derivados de compuestos heterociclicos sustituidos y su uso farmaceutico | |
| EA202092236A1 (ru) | Производные 2-аминопиридина и 2-аминопиримидина в качестве ингибиторов циклинзависимых киназ | |
| EA202190690A1 (ru) | Борсодержащие ингибиторы pde4 |